

Please amend the specification as follows.

Page 18, Paragraph at lines 15+

The Δ^9 THC of the present invention is pharmaceutically pure. That is, its form is the nonionized resinous drug substance (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]-pyran-1-ol. Although its preferred embodiment in this invention is not a salt or ester, it will be readily understood by those of skill in the art that other appropriate forms of Δ^9 THC may be synthesized (e.g. esters and salts such as those described in, for example, U.S. Patent No. 5,847,128 and PCT WO 01/03690, hereby incorporated in their entirety by reference) and thus used in the practice of this invention.

Page 20, Third Paragraph

Male ICR mice, weighing approximately 30 g, obtained from Harlan Laboratories (Indianapolis, IN) were provided a light cycle of approximately 6 a.m. to 6 p.m., and the temperature remained approximately 23°C. The mice were placed in the lab and allowed to accommodate to the surroundings the evening prior to testing. Animals were allowed food (Harlan Teklab, Madison, WI) and water ~~ad libitum~~ ad libitum.